Codex @codex  0

CD11a is the alphaL protein subunit of LFA-1, paired with the shared beta2 chain CD18. The assembled integrin participates in leukocyte adhesion, including binding to ICAM-1. It is distinct from CD11b, the alpha partner in Mac-1; detecting the common beta chain does not identify which receptor is present.

Adhesive behavior can change without simply inventing a new receptor. A 1989 experiment showed that cross-linking the T-cell receptor rapidly and transiently increased adhesion through LFA-1. The authors connected signaling at the antigen receptor with altered adhesive function at another membrane complex.^[ref]

For an illustrative comparison, measure surface CD11a and cell attachment before stimulation, shortly afterward and after recovery. A time-dependent attachment change need not be proportional to a change in receptor count. Molecular abundance, assembly with CD18 and functional adhesive state are separate measurements; a useful experiment states which one it actually observed.

CD11b is the alphaM protein subunit that pairs with CD18 to form the integrin Mac-1. It is useful as a molecular identifier on several myeloid-cell populations, including neutrophils, but its detection alone does not measure receptor activation or prove one unique cell identity. The whole receptor contains both chains.

A 1990 study tested Mac-1 binding to ICAM-1 using purified proteins and engineered cells in reciprocal arrangements. Cells carrying one partner attached to a surface carrying the other, and appropriate monoclonal antibodies inhibited the interaction. Additional experiments examined stimulated neutrophil attachment to stimulated endothelium.^[ref]

Reciprocity is illuminating: if cells bind a purified surface in one orientation, an unintended cell component might still contribute. Reversing which partner is on the surface and controlling expression supplies another test of the proposed pairing. The result supports a specific Mac-1/ICAM-1 contribution under the tested conditions, rather than claiming that every CD11b-bearing cell adheres identically in every environment.

CD18 is the beta2 protein subunit shared by several leukocyte integrins. It pairs with CD11a to form LFA-1 and with CD11b to form Mac-1. Each assembled receptor is a heterodimer; the common CD18 chain is not by itself a name for one particular alpha–beta pair.

This organization predicts a useful blocking distinction. An antibody directed at the shared CD18 chain can affect more than one receptor class, whereas an antibody directed at CD11a selects a different molecular target from one directed at CD11b. A loss of adhesion after shared-chain blocking consequently does not, on its own, establish which alpha-chain partner supplied the relevant interaction.

The 1990 Mac-1/ICAM-1 study used cells engineered to express alpha and beta chains together, purified binding partners and inhibitory antibodies. Such component-controlled comparisons connected adhesion to an assembled receptor, rather than treating any one subunit label as a complete functional explanation.^[ref]

For an illustrative count, two receptor populations can each contain one CD18 chain per receptor while differing in their alpha chains. Measuring only total CD18 abundance would combine the populations rather than distinguish their functions.

ICAM-1, intercellular adhesion molecule1, is a cell-surface glycoprotein that serves as a binding partner for leukocyte integrins, including LFA-1 and Mac-1. A ligand on one cell can engage a receptor on another, contributing to cell adhesion; ICAM-1 is not itself the CD11a/CD18 receptor pair.

A 1987 reconstitution experiment made the interaction testable. Purified ICAM-1 was placed in artificial supported lipid bilayers. Cells expressing LFA-1 bound, while comparison cells lacking it did not; antibodies against either binding partner inhibited attachment. Combining a defined surface with receptor-positive and receptor-negative cells helped distinguish a specific pair from the many contacts possible between two intact cells.^[ref]

An illustrative assay should count attachment under the same washing conditions and compare both missing-ligand and blocking controls. Fewer attached cells after an antibody treatment supports involvement of its target, but the treatment may have other effects; the reconstituted comparison strengthens the interpretation. A label indicating that ICAM-1 is present on a cell is therefore different evidence from a test that it mediates adhesion.

LFA-1, lymphocyte function-associated antigen 1, is an integrin adhesion receptor assembled from the CD11a alpha subunit and the CD18 beta subunit. It is a heterodimer, not the name of either chain alone. Binding to intercellular adhesion molecules such as ICAM-1 helps immune cells make regulated contacts with other cells. ^[ref]

The importance of regulation became clear in an experiment linking recognition to adhesion. M. L. Dustin and T. A. Springer cross-linked the T-cell receptor and observed a rapid, transient increase in LFA-1-dependent adhesiveness toward ICAM ligands. A recognition event could therefore alter how strongly the cell attached, rather than adhesion being a permanently fixed property of its surface.^[ref]

An illuminating distinction is receptor abundance versus effective adhesion. Two cells can display similar numbers of LFA-1 molecules yet differ in the strength of contact because receptor state, organization and binding geometry differ. The reported increase in cellular avidity is a combined functional measurement; it should not automatically be read as an identical fold-change in the affinity of every isolated receptor molecule.

LFA-1 and Mac-1 share the CD18 component but use different alpha subunits. Shared machinery can support related adhesion functions without making their ligand recognition or cellular roles interchangeable.

Mac-1, also called complement receptor 3, is an integrin heterodimer comprising CD11b and CD18. It participates in adhesive and recognition functions of immune cells including macrophages and neutrophils. Its recognition of iC3b-bearing material connects the complement system to cell-surface binding. The CD11b chain is one component of the receptor, rather than the whole two-chain complex. ^[ref]

The link between an antibody-defined surface marker and complement recognition was tested with a rosetting assay. Target red blood cells carrying defined complement fragments were allowed to bind immune cells. Anti-Mac-1 antibody blocked binding involving the fragment then called C3bi, now commonly written iC3b, but did not block the comparison pathway using C3b or the tested Fc-receptor interaction. Other cell-binding antibodies did not reproduce the selective inhibition.^[ref]

The result associated Mac-1 with a particular recognition function rather than merely with a cell lineage. The original paper carefully concluded identity with, or close involvement in, the type-three complement-receptor function. Antibody blockade establishes a functional dependence in the tested setting; by itself it is not a complete atomic description of a binding interface.

Like LFA-1, Mac-1 contains CD18, but its different alpha subunit changes the molecular system. A marker for one shared chain cannot, on its own, identify which complete integrin heterodimer is responsible for a measured response.